Baricitinib provides rapid and sustained improvements in absolute EASI and SCORAD outcomes in adults with moderate-to-severe atopic dermatitis

References

• Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73(6):1–9.
   Web of Science ®Google Scholar
• Boguniewicz M, Fonacier L, Guttman-Yassky E, et al. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120(1):10–22.e2.
   PubMed Web of Science ®Google Scholar
• Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1.
   PubMed Web of Science ®Google Scholar
• Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109–1122.
   PubMed Web of Science ®Google Scholar
• Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol. 2014;134(6):1527–1534.
   PubMed Web of Science ®Google Scholar
• Iannone M, Tonini G, Janowska A, et al. Definition of treatment goals in terms of clinician-reported disease severity and patient-reported outcomes in moderate-to-severe adult atopic dermatitis: a systematic review. Curr Med Res Opin. 2021;37(8):1295–1301.
   PubMed Web of Science ®Google Scholar
• Chopra R, Vakharia PP, Sacotte R, et al. Relationship between EASI and SCORAD severity assessments for atopic dermatitis. J Allergy Clin Immunol. 2017;140(6):1708–1710.e1.
   PubMed Web of Science ®Google Scholar
• Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1993;186(1):23–31.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682.
   PubMed Web of Science ®Google Scholar
• Leshem YA, Hajar T, Hanifin JM, et al. What the eczema area and severity index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol. 2015;172(5):1353–1357.
   PubMed Web of Science ®Google Scholar
• Schram ME, Spuls PI, Leeflang MM, et al. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy. 2012;67(1):99–106.
   PubMed Web of Science ®Google Scholar
• De Bruin-Weller M, Biedermann T, Bissonnette R, et al. Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies. Acta Derm Venereol. 2021;101(2):adv00402.
   PubMedGoogle Scholar
• Thyssen JP, Vestergaard C, Deleuran M, et al. European Task Force on Atopic Dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis. J Eur Acad Dermatol Venereol. 2020;34(12):e839–e842.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183(2):242–255.
   PubMed Web of Science ®Google Scholar
• Reich K, Kabashima K, Peris K, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(12):1333–1343.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Simpson EL, Wollenberg A, et al. Long-term efficacy of baricitinib in adults with moderate to severe atopic dermatitis who were treatment responders or partial responders: an extension study of 2 randomized clinical trials. JAMA Dermatol. 2021;157(6):691–699.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency Olumiant: EPAR – Product Information; 2021.
   Google Scholar
• Hongbo Y, Thomas CL, Harrison MA, et al. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol. 2005;125(4):659–664.
   PubMed Web of Science ®Google Scholar
• Rogner D, Biedermann T, Lauffer F. Treatment of atopic dermatitis with baricitinib: first real-life experience. Acta Derm Venereol. 2022;102:adv00677.
   PubMed Web of Science ®Google Scholar
• Uchiyama A, Fujiwara C, Inoue Y, et al. Real-world effectiveness and safety of baricitinib in Japanese patients with atopic dermatitis: a single-center retrospective study. J Dermatol. 2022;49(4):469–471.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Simpson, EL, Armstrong AW, et al. Expert perspectives on key parameters that impact interpretation of randomized clinical trials in moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2022;23(1):1–11.
   PubMed Web of Science ®Google Scholar
• Heratizadeh A, Haufe E, Stölzl D, et al. Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany. J Eur Acad Dermatol Venereol. 2020;34(6):1263–1272.
   PubMed Web of Science ®Google Scholar
• Ariëns LFM, van der Schaft J, Bakker DS, et al. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: first clinical and biomarker results from the BioDay registry. Allergy. 2020;75(1):116–126.
   PubMed Web of Science ®Google Scholar
• Buhl T, Rosmarin D, Serra-Baldrich E, et al. Itch and sleep improvements with baricitinib in patients with atopic dermatitis: a post-hoc analysis of 3 phase 3 studies. Dermatol Ther. 2021;11(3):971–982.
   Web of Science ®Google Scholar
• Reich K, DeLozier AM, Nunes FP,et al., Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials. J Dermatolog Treat. 2022;33(3):1521–1530.
   Google Scholar
• Yosipovitch G, Papp K, Forman S, et al. The contribution of itch and skin severity improvements to the dermatology life quality index in patients with atopic dermatitis in baricitinib phase III trials. Br J Dermatol. 2022;186(6):1047–1049.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Nakahara T, Maari C, et al. Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 phase 3 randomized trial. J Eur Acad Dermatol Venereol. 2021;35(7):1543–1552.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Christen-Zäch S, Taieb A, et al. ETFAD/EADV Eczema Task Force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717–2744.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bruin-Weller M, Flohr C, et al. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. J Am Acad Dermatol. 2017;77(4):623–633.
   PubMed Web of Science ®Google Scholar